Wainwright Keeps Their Buy Rating on Nicox SA (0RCQ)

Wainwright reiterates a Buy rating on Nicox SA following a June 5 update. Ram Selvaraju of H.C. Wainwright assigns a €1.00 price target to Nicox. Nicox closed last Friday at €0.37 per share, indicating meaningful upside if the target is realized. The company carries a market capitalization of about €35.01 million and a negative P/E ratio of -13.66. TipRanks notes Selvaraju as a five-star analyst with an average return of 18.4% and a 50.20% success rate. Selvaraju’s call comes amid mixed market commentary, with The Street broadly signaling a Hold for Nicox. The note references TipRanks' assessment of Selvaraju's track record to contextualize the Buy rating. Nicox's small-cap biotech profile and negative earnings multiples contribute to the stock's high-risk, high-reward profile. The June 5 update is the primary driver cited for this note, according to Wainwright. Investors should weigh the €1.00 target against the current €0.37 share price within the biotech risk framework.